Dr. Jeffrey Schriber, director of hematologic malignancies at Cancer Treatment Centers of America® (CTCA) Phoenix, shared his expertise during an interview with CURE on how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.